IP Library Granted Patent US 9,365,611
Granted Patent B2
US 9,365,611 · App. 14/785,192 · Granted Jun 14, 2016

19-NOR neuroactive steroids and methods of use thereof

Inventors: Gabriel Martinez Botella (Wayland, MA); Boyd L. Harrison (Princeton Junction, NJ); Albert Jean Robichaud (Ringoes, NJ); Francesco G. Salituro (Marlborough, MA); Richard Thomas Beresis (Shanghai, CN)
Assignee: SAGE THERAPEUTICS, INC.
C07J43/003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,365,611
App. No.
14/785,192
Granted
Jun 14, 2016
Kind
B2
Abstract

Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, and status epilepticus.

Claims (66)

1. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof;

wherein:

represents a single or double bond as valency permits;

A is of Formula (A-1) or Formula (A-2):

wherein the point of attachment is at G 1 or G 2 in Formula (A-1) and the point of attachment is at G 2 or G 3 in Formula (A-2);

G 1 is N, NR N1 , O, S, C, or C—R G1 as valency permits;

G 2 is N, NR N2 , O, S, C, —C═N—, or C—R G2 as valency permits;

G 3 is N, NR N3 , O, S, C, or C—R G3 as valency permits;

G 4 is N, NR N4 , C—R G4 , or C—(R G4 ) 2 as valency permits;

G 5 is N, NR N5 , C—R G5 , or C—(R G5 ) 2 as valency permits;

G 6 is N, NR N6 , C—R G6 , or C—(R G6 ) 2 as valency permits; and

G 7 is N, NR N7 , C—R G7 , or C—(R G7 ) 2 as valency permits;

each instance of R G1 , R G2 , R G3 , R G4 , R G5 , R G6 , and R G7 is, independently, hydrogen, halogen, —NO 2 , —CN, —OR GA , —N(R GA ) 2 , —C(═O)R GA , —C(═O)OR GA , —OC(═O)R GA , —OC(═O)OR GA , —C(═O)N(R GA ) 2 , —N(R GA )C(═O)R GA , —OC(═O)N(R GA ) 2 , —N(R GA )C(═O)OR GA , —S(═O) 2 R GA , —S(═O) 2 OR GA , —OS(═O) 2 R GA , —S(═O) 2 N(R GA ) 2 , —N(R GA )S(═O) 2 R GA , —S(═O)R GA , —S(═O)OR GA , —OS(═O)R GA , —S(═O)N(R GA ) 2 , —N(R GA )S(═O)R GA , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 carbocyclyl, substituted or unsubstituted 3- to 6-membered heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

each instance of R N1 , R N2 , R N3 , R N4 , R N5 , R N6 , and R N7 is independently hydrogen, substituted or unsubstituted C 1-6 alkyl, or a nitrogen protecting group;

each instance of R GA is independently hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 carbocyclyl, substituted or unsubstituted 3- to 6-membered heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to oxygen, a nitrogen protecting group when attached to nitrogen, or two R GA groups are taken with the intervening atoms to form a substituted or unsubstituted carbocyclic or heterocyclic ring;

R 1 is substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, or substituted or unsubstituted C 3-6 carbocyclyl;

R 2 is hydrogen, halogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3-6 carbocyclyl, or —OR A2 , wherein R A2 is hydrogen or substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, or substituted or unsubstituted C 3-6 carbocyclyl;

R 3a is hydrogen or —OR A3 , wherein R A3 is hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, or substituted or unsubstituted C 3-6 carbocyclyl, and R 3b is hydrogen; or R 3a and R 3b are joined to form an oxo (═O) group;

each of R 4a or R 4b is independently hydrogen, substituted or unsubstituted C 1-6 alkyl, or halogen;

provided if bond p is a double bond, then bond q is a single bond, provided if bond q is a double bond, then bond p is a single bond and R 4b is absent; and provided if both bonds p and q are single bonds, then the hydrogen at C5 is in the alpha or beta configuration.

2. A compound of claim 1 , wherein the compound is of Formula (II):

or a pharmaceutically acceptable salt thereof.

3. A compound of claim 1 , wherein the compound is of Formula (II-a):

or a pharmaceutically acceptable salt thereof.

4. A compound of claim 1 , wherein the compound is one of the following formulae:

or a pharmaceutically acceptable salt thereof.

5. A compound of claim 1 , wherein the compound is of one of the following formulae:

or a pharmaceutically acceptable salt thereof.

6. A compound of claim 1 , wherein the compound is of Formula (II-b):

or a pharmaceutically acceptable salt thereof.

7. A compound of claim 1 , wherein the compound is one of the following formulae:

or a pharmaceutically acceptable salt thereof.

8. A compound of claim 1 , wherein the compound is one of the following formulae:

or a pharmaceutically acceptable salt thereof.

9. A compound of claim 1 , wherein the compound is of Formula (III):

or a pharmaceutically acceptable salt thereof.

10. A compound of claim 1 , wherein the compound is of Formula (III-a):

or a pharmaceutically acceptable salt thereof.

11. A compound of claim 1 , wherein the compound is of Formula (III-b):

or a pharmaceutically acceptable salt thereof.

12. A compound of claim 1 , wherein the compound is of Formula (III-b1):

or a pharmaceutically acceptable salt thereof.

13. A compound of claim 1 , wherein the compound is of Formula (IV):

or a pharmaceutically acceptable salt thereof.

14. A compound of claim 1 , wherein the compound is of Formula (IV-a):

or a pharmaceutically acceptable salt thereof.

15. A compound of claim 1 , wherein the compound is of Formula (IV-a1):

or a pharmaceutically acceptable salt thereof.

16. A compound of claim 1 , wherein the compound is of one of the following formulae:

or a pharmaceutically acceptable salt thereof.

17. A compound of claim 1 , wherein the compound is of Formula (V):

or a pharmaceutically acceptable salt thereof.

18. A compound of claim 1 , wherein the compound is of Formula (VI):

or a pharmaceutically acceptable salt thereof.

19. A compound of claim 1 , wherein the compound is of Formula (VII):

or a pharmaceutically acceptable salt thereof.

20. A compound of claim 1 , wherein the compound is of Formula (VIII):

or a pharmaceutically acceptable salt thereof.

21. A compound of claim 1 , wherein the compound is of Formula (IX):

or a pharmaceutically acceptable salt thereof.

22. A compound of claim 1 , wherein the compound is of Formula (X):

or a pharmaceutically acceptable salt thereof.

23. The compound of claim 1 , wherein the compound is selected from the group consisting of:

24. The compound of claim 1 , wherein the compound is selected from the group consisting of:

25. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

Assignments (2)
CHANGE OF NAME Recorded Aug 18, 2026
From: SAGE THERAPEUTICS, INC.
To: SAGE THERAPEUTICS, LLC
Reel/Frame 075866/0450 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2016
From: MARTINEZ BOTELLA, GABRIEL; HARRISON, BOYD L.; ROBICHAUD, ALBERT JEAN; SALITURO, FRANCESCO G.; BERESIS, RICHARD THOMAS
To: SAGE THERAPEUTICS, INC.
Reel/Frame 038435/0661 →
Continuity (1)
Related Publication 20160083418A1 · Mar 24, 2016